MLL partial tandem duplication leukemia cells are sensitive to small molecule DOT1L inhibition

Haematologica

Volumn 100, Issue 5, 2015, Pages e190-e193

  Kühn, Michael W M ^a   Hadler, Michael J ^a   Daigle, Scott R ^b   Koche, Richard P ^a   Krivtsov, Andrei V ^a   Olhava, Edward J ^b   Caligiuri, Michael A ^c   Huang, Gang ^d   Bradner, James E ^e   Pollock, Roy M ^b   Armstrong, Scott A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b EPIZYME INC   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

DOT1L inhibition; Leukemia; MLL PTD

Indexed keywords

PINOMETOSTAT; ANTINEOPLASTIC AGENT; DOT1L PROTEIN, HUMAN; ENZYME INHIBITOR; HISTONE; METHYLTRANSFERASE; MIXED LINEAGE LEUKEMIA PROTEIN;

ACUTE MYELOBLASTIC LEUKEMIA; ARTICLE; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; FLOW CYTOMETRY; GENE DELETION; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; IC50; LEUKEMIA; LEUKEMIA CELL; MIXED LINEAGE LEUKEMIA; NEXT GENERATION SEQUENCING; PARTIAL TANDEM DUPLICATION LEUKEMIA CELL; TUMOR GROWTH; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CELL SURVIVAL; DRUG EFFECTS; DRUG RESISTANCE; GENE DUPLICATION; GENETICS; METABOLISM; PATHOLOGY; TANDEM REPEAT; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; GENE DUPLICATION; HISTONES; HUMANS; LEUKEMIA; METHYLTRANSFERASES; MYELOID-LYMPHOID LEUKEMIA PROTEIN; TANDEM REPEAT SEQUENCES;

EID: 84929100337     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2014.115337     Document Type: Article

References (15)

1. Döhner K, Döhner H. Molecular characterization of acute myeloid leukemia. Haematologica. 2008;93(7):976-982.
2. Whitman SP, Caligiuri MA, Maharry K, Radmacher MD, Kohlschmidt J, Becker H, et al. The MLL partial tandem duplication in adults aged 60 years and older with de novo cytogenetically normal acute myeloid leukemia. Leukemia. 2012;26(7):1713-1717.
3. Whitman SP, Ruppert AS, Marcucci G, Mrozek K, Paschka P, Langer C, et al. Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study. Blood. 2007;109(12):5164-5167.
4. Bacher U, Haferlach T, Kern W, Haferlach C, Schnittger S. A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia. Haematologica. 2007;92(6):744-752.
5. Patel JP, Gonen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012;366(12):1079-1089.
6. Döhner K, Tobis K, Ulrich R, Frohling S, Benner A, Schlenk RF, et al. Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: a study of the Acute Myeloid Leukemia Study Group Ulm. J Clin Oncol. 2002;20(15):3254-3261.
7. Mrozek K, Marcucci G, Paschka P, Whitman SP, Bloomfield CD. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? Blood. 2007;109(2):431-448.
8. Bernt KM, Zhu N, Sinha AU, Vempati S, Faber J, Krivtsov AV, et al. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell. 2011;20(1):66-78.
9. Neff T, Armstrong SA. Recent progress toward epigenetic therapies: the example of mixed lineage leukemia. Blood. 2013;121(24):4847-4853.
10. Nguyen AT, Taranova O, He J, Zhang Y. DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis. Blood. 2011;117(25):6912-6922.
11. Deshpande AJ, Chen L, Fazio M, Sinha AU, Bernt KM, Banka D, et al. Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l. Blood. 2013;121(13):2533-2541.
12. Chen L, Deshpande AJ, Banka D, Bernt KM, Dias S, Buske C, et al. Abrogation of MLL-AF10 and CALM-AF10-mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1l. Leukemia. 2013;27(4):813-822.
13. Daigle SR, Olhava EJ, Therkelsen CA, Majer CR, Sneeringer CJ, Song J, et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell. 2011;20(1):53-65.
14. Daigle SR, Olhava EJ, Therkelsen CA, Basavapathruni A, Jin L, Boriack-Sjodin PA, et al. Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood. 2013;122(6):1017-1025.
15. Bernt KM, Armstrong SA. A role for DOT1L in MLL-rearranged leukemias. Epigenomics. 2011;3(6):667-670.